(en-TREK-tih-nib)
This page contains brief information about entrectinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Entrectinib is approved to treat:
- Non-small cell lung cancer that is ROS1 positive. It is used in adults whose cancer has spread to other parts of the body.
- Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins. It is used in adults and in children aged 1 month and older whose cancer has spread to other parts of the body or cannot be removed by surgery and has gotten worse after other treatment or cannot be treated with other therapies.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that entrectinib provides a clinical benefit in these patients.
Entrectinib is also being studied in the treatment of other types of cancer.
More About Entrectinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Entrectinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Entrectinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
